Medimmune
  • ABOUT MEDIMMUNE
    • Key Facts & Figures
    • Products
    • Facilities
    • At the Forefront
  • OUR CULTURE
    • History & Highlights
    • Visionaries at MedImmune
    • Executive Team
    • Corporate Responsibility
  • R & D
    • Pipeline
    • Drug Phase Chart
    • Biologics
    • Technologies & Approaches
    • Partnering
  • VENTURES
    • Investing in Our Future
    • Portfolio
  • PRESS ROOM
  • CAREERS
  • CONTACT
  • Home >
    • News & Media

News and Media

For press releases:

2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

Receive E-mail alerts

Subscribe to RSS feeds

December 27, 2001
MedImmune Completes Enrollment in Clinical Trials For Synagis(R) and Siplizumab
December 21, 2001
MedImmune Has Held License to Genentech Antibody Patent Since 1997
December 3, 2001
MedImmune to Acquire Aviron in Exchange Offer Valued at $1.5 Billion
- Aviron's FluMist(TM) Expected to Strengthen MedImmune's Industry-Leading Franchise in Infectious Disease
November 6, 2001
MedImmune Presents Data on Subcutaneous Ethyol(R) At American Society for Therapeutic Radiology and Oncology Annual Meeting
October 25, 2001
MedImmune Licenses Cancer Target from Purdue Research Foundation
Company Focused on Building Oncology Franchise -
October 22, 2001
New Data Presented on Synagis® And RSV at American Academy of Pediatrics 2001 National Conference
October 18, 2001
MedImmune Reports Results for First Nine Months of 2001
October 12, 2001
MedImmune to Announce Third Quarter 2001 Financial Results on October 18, 2001
September 24, 2001
Clinical Data for Siplizumab Presented at European Psoriasis Meeting
September 17, 2001
MedImmune Initiates Large Phase II Study with Siplizumab in Psoriasis Patients
September 10, 2001
MedImmune Accelerates Reacquisition of U.S. Rights to Ethyol® from Alza
August 23, 2001
MedImmune Announces Six Executive Promotions and Appointments
August 6, 2001
Medimmune Initiates Clinical Study With Vitaxin™ In Rheumatoid Arthritis Patients
July 25, 2001
MedImmune Reports Results For First Six Months Of 2001
July 25, 2001
MedImmune Initiates Additional Clinical Testing Of Siplizumab In Psoriasis Patients
July 23, 2001
MedImmune Launches Enhanced Corporate Website
July 20, 2001
MedImmune to Announce Second Quarter 2001 Financial Results on July 25, 2001
July 16, 2001
MedImmune Initiates Phase I/II Clinical Study With VitaxinTM
June 23, 2001
Initial Clinical Results For MEDI-507 As Psoriasis Treatment Presented At International Psoriasis Symposium
June 6, 2001
MedImmune Expands Phase II Psoriasis Program for MEDI-507
May 7, 2001
MedImmune Announces Relocation of Headquarters
April 19, 2001
MedImmune Reports Record First Quarter Results
April 19, 2001
MedImmune and Genaera Enter Agreement to Develop Products Targeting Respiratory Disease
April 9, 2001
MedImmune to Announce First Quarter 2001 Financial Results on April 19, 2001
April 2, 2001
MedImmune Initiates Phase II Clinical Trials for MEDI-507 in Psoriasis Patients
March 13, 2001
MedImmune Initiates New Clinical Trials
February 22, 2001
MedImmune Signs Agreement with Targesome for Development of Vitaxin for Targeted Radiotherapy
February 15, 2001
Gregory S. Patrick Joins MedImmune as Senior Vice President and Chief Financial Officer
January 25, 2001
MedImmune Sets New Revenue and Earnings Records
January 12, 2001
MedImmune to Announce Fourth Quarter 2000 Financial Results on January 25, 2001
  • Terms and Conditions
  • |
  • Privacy Policy
  • |
  • Site Map
  • |
  • Contact Us
  • |
  • Glossary
Copyright © 2009 MedImmune, LLC. All rights reserved.